Heparin allergy: Delayed type allergy to subcutaneous heparin injections;Heparinallergie: Spättypallergie gegen subkutane heparininjektion

Allergo Journal

Volumn 15, Issue 7, 2006, Pages 501-506

  Trautmann, Axel ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Adverse drug reaction; Challenge test; Delayed type allergic hypersensitivity; Heparin; Heparinoid

Indexed keywords

CERTOPARIN; DALTEPARIN; DANAPAROID; DESULFATOHIRUDIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARINOID; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MONO EMBOLEX; NADROPARIN; PENTOSAN POLYSULFATE; REVIPARIN; TINZAPARIN;

ARTICLE; DELAYED HYPERSENSITIVITY; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REGIMEN; DRUG MECHANISM; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INJECTION SITE ERYTHEMA; PATCH TEST; PROVOCATION TEST; SKIN NECROSIS;

EID: 33751074700     PISSN: 09418849     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03361605     Document Type: Article

References (52)

1. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, Brockow K, Pichler WJ, Demoly P; European Network for Drug Allergy (ENDA); EAACI interest group on drug hypersensitivity. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58: 854-63
2. Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 2003; 101: 31-7
3. Argaud L, Guerin C, Thomas L, Fournier C. Extensive coumarin-induced skin necrosis in a patient with acquired protein C deficiency. Intensive Care Med 2001; 27: 1555
4. Balestra B. [Skin necrosis: a paradoxical complication of anticoagulation.] Schweiz Med Wochenschr 1995; 125: 361-4
5. Bauer KA. Coumarin-induced skin necrosis. Arch Dermatol 1993; 129: 766-8
6. Bernstein IL. Anaphylaxis to heparin sodium; report of a case, with immunologic studies. JAMA 1956; 161: 1379-81
7. Bircher AJ, Flückiger R, Buchner SA. Eczematous infiltrated plaques to subcutaneous heparin: a type IV allergic reaction. Br J Dermatol 1990; 123: 507-14
8. Blann AD, Landray MJ, Lip GY. ABC of antithrombotic therapy: an overview of antithrombotic therapy. BMJ 2002; 325: 762-5
9. Boehncke WH, Weber L, Gall H. Tolerance to intravenous administration of heparin and heparinoid in a patient with delayed-type hypersensitivity to heparins and heparinoids. Contact Dermatitis 1996; 35: 73-5
10. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57: 45-51
11. Demoly P, Bousquet J. Drug allergy diagnosis work up. Allergy 2002; 57: 37-40
12. 4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br J Haematol 2002; 116: 887-91
13. Estrada Rodriguez JL, Gozalo RF, Ortiz DU, Matilla B, Rodriguez Prieto MA, Gonzalez Moran NA. Generalized eczema induced by nadroparin. J Investig Allergol Clin Immunol 2003; 13: 69-70
14. Gaigl Z, Pfeuffer P, Raith P, Bröcker EB, Trautmann A. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study. Br J Haematol 2005; 128: 389-92
15. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338-400
16. Grassegger A, Fritsch P, Reider N. Delayed-type hypersensitivity and cross-reactivity to heparins and danaparoid: a prospective study. Dermatol Surg 2001; 27: 47-52
17. Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res 2005; 13: 1-12
18. Greiner D, Schöfer H. [Allergic drug exanthema to heparin. Cutaneous reactions to high molecular and fractionated heparin.] Hautarzt 1994; 45: 569-72
19. Guillet G, Delaire P, Plantin P, Guillet MH. Eczema as a complication of heparin therapy. J Am Acad Dermatol 1989; 20: 1130-2
20. Harenberg J, Hoffmann U, Huhle G, Winkler M, Bayerl C. Cutaneous reactions to anticoagulants. Recognition and management. Am J Clin Dermatol 2001; 2: 69-75
21. Hirsch K, Ludwig RJ, Lindhoff-Last E, Kaufmann R, Boehncke WH. Intolerance of fondaparinux in a patient allergic to heparins. Contact Dermatitis 2004; 50: 383-4
22. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004; 164: 361-9
23. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64-94
24. Hohenstein E, Tsakiris D, Bircher AJ. Delayed-type hypersensitivity to the ultra-low-molecular-weight heparin fondaparinux. Contact Dermatitis 2004; 51: 149-51
25. Hyers TM. Management of venous thromboembolism: past, present, and future. Arch Intern Med 2003; 163: 759-68
26. James RF. Rectus sheath haematoma. Lancet 2005; 365: 1824
27. Jappe U, Juschka U, Kuner N, Hausen BM, Krohn K. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases. Contact Dermatitis 2004; 51: 67-72
28. Jappe U, Reinhold D, Bonnekoh B. Arthus reaction to lepirudin, a new recombinant hirudin, and delayed-type hypersensitivity to several heparins and heparinoids, with tolerance to its intravenous administration. Contact Dermatitis 2002; 46: 29-32
29. Keam SJ, Goa KL. Fondaparinux sodium. Drugs 2002; 62: 1673-85
30. Kim KH, Lynfield Y. Enoxaparin-induced generalized exanthema. Cutis 2003; 72: 57-60
31. Klein GF, Kofler H, Wolf H, Fritsch PO. Eczema-like, erythematous, infiltrated plaques: a common side effect of subcutaneous heparin therapy. J Am Acad Dermatol 1989; 21: 703-7
32. Koch P. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux. Contact Dermatitis 2003; 49: 276-80
33. Koch P, Reinhold S, Busch C. Delayed allergic skin reactions to subcutaneous heparins. Tolerance of 2 recombinant hirudins. Contact Dermatitis 2000; 42: 278-9
34. Korstanje MJ, Bessems PJ, Hardy E, Staak WJ van de. Delayed-type hypersensitivity reaction to heparin. Contact Dermatitis 1989; 20: 383-4
35. Kroon C, de Boer A, Kroon JM, Schoemaker HC, van den Meer FJ, Cohen AF. Influence of skinfold thickness on heparin absorption. Lancet 1991; 337: 945-6
36. Liew G, Campbell C, Thursby P. Delayed-type hyper-sensitivity to subcutaneous heparin with tolerance of i.v. administration. Aust N Z J Surg 2004; 74: 1020-1
37. Ludwig RJ, Beier C, Lindhoff-Last E, Kaufmann R, Boehncke WH. Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans. Contact Dermatitis 2003; 49: 158-9
38. Maetzke J, Hinrichs R, Staib G, Scharffetter-Kochanek K. Fondaparinux as a novel therapeutic alternative in a patient with heparin allergy. Allergy 2004; 59: 237-8
39. Oldhoff JM, Bihari IC, Knol EF, Bruijnzeel-Koomen CA, Bruin-Weller MS. Atopy patch test in patients with atopic eczema/dermatitis syndrome: comparison of petrolatum and aqueous solution as a vehicle. Allergy 2004; 59: 451-6
40. Parody R, Oliver A, Souto JC, Fontcuberta J. Fondaparinux (Arixtra) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica 2003; 88: 32
41. Patrizi A, Di L, Patrone P. Generalized reaction to subcutaneous heparin. Contact Dermatitis 1989; 20: 309-10
42. Rajka G, Skog E. On the question of heparin hypersensitivity. Acta Derm Venereol 1962; 42: 27-34
43. Schiffner R, Glassl A, Landthaler M, Stolz W. Tolerance of desirudin in a patient with generalized eczema after intravenous challenge with heparin and a delayed-type skin reaction to high and low molecular weight heparins and heparinoids. Contact Dermatitis 2000; 42: 49
44. Shelley WB, Sayen JJ. Heparin necrosis: an anticoagulant-induced cutaneous infarct. J Am Acad Dermatol 1982; 7: 674-7
45. Trautmann A, Bröcker EB, Klein CE. Intravenous challenge with heparins in patients with delayed-type skin reactions after subcutaneous administration of the drug. Contact Dermatitis 1998; 39: 43-4
46. Trautmann A, Heparinallergie. In: Trautmann A. Allergiediagnose, Allergietherapie. Stuttgart - New York: Thieme, 2006: 246-9
47. Utikal J, Peitsch WK, Booken D, Velten F, Dempfle CE, Goerdt S, Bayerl C. Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy. Thromb Haemost 2005; 94: 895-6
48. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 311-37
49. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 2005; 127: 1857-61
50. Wattiaux MJ, Herve R, Robert A, Cabane J, Housset B, Imbert JC. Coumarin-induced skin necrosis associated with acquired protein S deficiency and antiphospholipid antibody syndrome. Arthritis Rheum 1994; 37: 1096-100
51. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res 2002; 106: 275-84
52. Yates P, Jones S. Heparin skin necrosis - an important indicator of potentially fatal heparin hypersensitivity. Clin Exp Dermatol 1993; 18: 138-41